Zhejiang East Asia Pharmaceutical Co., Ltd. (SHA:605177)
China · Delayed Price · Currency is CNY 21.72
+0.19 (0.88%)
Feb 13, 2026, 3:00 PM CST
SHA:605177 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 821.8 | 1,188 | 1,351 | 1,174 | 702.06 | 878.65 |
Other Revenue | 9.76 | 9.76 | 5.86 | 5.28 | 10.16 | 3.02 |
| 831.56 | 1,198 | 1,356 | 1,180 | 712.22 | 881.67 | |
Revenue Growth (YoY) | -36.76% | -11.66% | 15.00% | 65.62% | -19.22% | -10.77% |
Cost of Revenue | 742.34 | 1,004 | 1,008 | 913.49 | 521.62 | 588.04 |
Gross Profit | 89.22 | 194.21 | 348.75 | 266.06 | 190.6 | 293.63 |
Selling, General & Admin | 174.33 | 179.97 | 146.85 | 122.72 | 116.33 | 126.75 |
Research & Development | 116.11 | 117.02 | 81.74 | 44.95 | 37.29 | 38.41 |
Other Operating Expenses | 11.64 | 6.27 | 5.6 | 8.57 | 5.2 | 11.2 |
Operating Expenses | 297.01 | 304.11 | 236.91 | 177.54 | 157.81 | 177.22 |
Operating Income | -207.79 | -109.91 | 111.84 | 88.52 | 32.79 | 116.41 |
Interest Expense | -9.77 | -2.04 | -3.6 | -0.84 | -0.22 | -0.66 |
Interest & Investment Income | 7.82 | 9.62 | 18.26 | 21.27 | 28.97 | 4.43 |
Currency Exchange Gain (Loss) | 3.13 | 3.13 | 0.8 | 2.22 | -0.68 | -2.1 |
Other Non Operating Income (Expenses) | 2.33 | -1.09 | -0.82 | -0.51 | -0.56 | -0.39 |
EBT Excluding Unusual Items | -204.27 | -100.29 | 126.48 | 110.66 | 60.3 | 117.68 |
Gain (Loss) on Sale of Assets | -18.27 | -15.73 | -5.69 | -5.54 | -4.05 | -2.45 |
Asset Writedown | -42.57 | -11.37 | - | - | - | - |
Other Unusual Items | 10.08 | 9.22 | 13.9 | 9.97 | 20.81 | 14.96 |
Pretax Income | -255.03 | -118.17 | 134.69 | 115.09 | 77.06 | 130.19 |
Income Tax Expense | -36.73 | -17.47 | 13.44 | 10.67 | 8.57 | 15.71 |
Earnings From Continuing Operations | -218.3 | -100.7 | 121.25 | 104.43 | 68.49 | 114.48 |
Minority Interest in Earnings | 0.06 | 0.04 | - | - | - | - |
Net Income | -218.24 | -100.66 | 121.25 | 104.43 | 68.49 | 114.48 |
Net Income to Common | -218.24 | -100.66 | 121.25 | 104.43 | 68.49 | 114.48 |
Net Income Growth | - | - | 16.11% | 52.46% | -40.17% | -31.99% |
Shares Outstanding (Basic) | 113 | 112 | 113 | 114 | 114 | 87 |
Shares Outstanding (Diluted) | 113 | 112 | 125 | 114 | 114 | 87 |
Shares Change (YoY) | -21.22% | -10.52% | 10.13% | -0.57% | 30.62% | 2.79% |
EPS (Basic) | -1.93 | -0.90 | 1.07 | 0.92 | 0.60 | 1.31 |
EPS (Diluted) | -1.93 | -0.90 | 0.97 | 0.92 | 0.60 | 1.31 |
EPS Growth | - | - | 5.44% | 53.33% | -54.20% | -33.84% |
Free Cash Flow | -410.49 | -368.16 | -311.53 | -158.17 | -145.57 | 85.82 |
Free Cash Flow Per Share | -3.62 | -3.29 | -2.49 | -1.39 | -1.27 | 0.98 |
Dividend Per Share | - | - | 0.327 | 0.290 | 0.200 | 0.350 |
Dividend Growth | - | - | 12.63% | 45.00% | -42.86% | 94.44% |
Gross Margin | 10.73% | 16.21% | 25.71% | 22.56% | 26.76% | 33.30% |
Operating Margin | -24.99% | -9.17% | 8.24% | 7.51% | 4.60% | 13.20% |
Profit Margin | -26.25% | -8.40% | 8.94% | 8.85% | 9.62% | 12.98% |
Free Cash Flow Margin | -49.36% | -30.73% | -22.97% | -13.41% | -20.44% | 9.73% |
EBITDA | -58.79 | 21.69 | 220.24 | 180.68 | 101.97 | 179.39 |
EBITDA Margin | -7.07% | 1.81% | 16.24% | 15.32% | 14.32% | 20.35% |
D&A For EBITDA | 149 | 131.6 | 108.4 | 92.15 | 69.18 | 62.98 |
EBIT | -207.79 | -109.91 | 111.84 | 88.52 | 32.79 | 116.41 |
EBIT Margin | -24.99% | -9.17% | 8.24% | 7.51% | 4.60% | 13.20% |
Effective Tax Rate | - | - | 9.98% | 9.27% | 11.12% | 12.06% |
Revenue as Reported | 831.56 | 1,198 | 1,356 | 1,180 | 712.22 | 881.67 |
Advertising Expenses | - | 3.23 | 2.5 | 0.08 | 1.74 | 2.13 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.